Currently, the first line of treatment for NSCLC are EGFR inhibitors (erlotinib, gefitinib) which are known to benefit patients harboring specific activating somatic mutations (exon 19 deletion or exon 21 substitution (L585R) or exon 18 substitution (G719C, G719S, G719A)) in the kinase domain of EGFR [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.